Literature DB >> 28893365

Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis.

Jonathan A Dranoff1.   

Abstract

Coffee is acknowledged as the most widely used drug worldwide. Coffee is also a foodstuff, so its use is often used to satisfy dietary urges. When used as a drug, coffee is normally consumed as a stimulant rather than to treat or prevent particular diseases. Recently, coffee consumption has been inversely related to progression of liver fibrosis to cirrhosis and even hepatocellular carcinoma. Experiments in cellular and animal models have provided biological plausibility for coffee as an antifibrotic agent in the liver. A recent article examined one of the key questions regarding the antifibrotic role of coffee-specifically what is the primary antifibrotic agent in coffee? This article briefly reviews the relevant issues with regard to coffee as an antifibrotic agent for patients with chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28893365      PMCID: PMC5885142          DOI: 10.3727/105221617X15046391179559

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  7 in total

1.  Coffee, caffeine, and the risk of liver cirrhosis.

Authors:  G Corrao; A Zambon; V Bagnardi; A D'Amicis; A Klatsky
Journal:  Ann Epidemiol       Date:  2001-10       Impact factor: 3.797

2.  Association of coffee drinking with total and cause-specific mortality.

Authors:  Neal D Freedman; Yikyung Park; Christian C Abnet; Albert R Hollenbeck; Rashmi Sinha
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

3.  Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study.

Authors:  Louise J M Alferink; Juliana Fittipaldi; Jessica C Kiefte-de Jong; Pavel Taimr; Bettina E Hansen; Herold J Metselaar; Josje D Schoufour; M Arfan Ikram; Harry L A Janssen; Oscar H Franco; Sarwa Darwish Murad
Journal:  J Hepatol       Date:  2017-06-01       Impact factor: 25.083

4.  Coffee consumption prevents fibrosis in a rat model that mimics secondary biliary cirrhosis in humans.

Authors:  Jonathan Arauz; Natanael Zarco; Erika Hernández-Aquino; Marina Galicia-Moreno; Liliana Favari; José Segovia; Pablo Muriel
Journal:  Nutr Res       Date:  2017-03-16       Impact factor: 3.315

Review 5.  The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis.

Authors:  Daniel Karin; Yukinori Koyama; David Brenner; Tatiana Kisseleva
Journal:  Differentiation       Date:  2016-08-31       Impact factor: 3.880

6.  How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations.

Authors:  Jonathan A Dranoff; Jordan J Feld; Elise G Lavoie; Michel Fausther
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

Review 7.  I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis.

Authors:  Jordan J Feld; Élise G Lavoie; Michel Fausther; Jonathan A Dranoff
Journal:  F1000Res       Date:  2015-04-21
  7 in total
  7 in total

1.  Caffeine inhibits hypoxia-induced renal fibroblast activation by antioxidant mechanism.

Authors:  Angkhana Nilnumkhum; Rattiyaporn Kanlaya; Sunisa Yoodee; Visith Thongboonkerd
Journal:  Cell Adh Migr       Date:  2019-12       Impact factor: 3.405

Review 2.  Can coffee silverskin be a useful tool to fight metabolic syndrome?

Authors:  Nelson Andrade; Juliana A Barreto Peixoto; M Beatriz P P Oliveira; Fátima Martel; Rita C Alves
Journal:  Front Nutr       Date:  2022-09-21

3.  Analysis of Volatile Compounds, Composition, and Thermal Behavior of Coffee Beans According to Variety and Roasting Intensity.

Authors:  Thomas Dippong; Monica Dan; Melinda Haydee Kovacs; Emoke Dalma Kovacs; Erika Andrea Levei; Oana Cadar
Journal:  Foods       Date:  2022-10-10

4.  Characterization of Arabica and Robusta Coffees by Ion Mobility Sum Spectrum.

Authors:  Paweł Piotr Konieczka; María José Aliaño-González; Marta Ferreiro-González; Gerardo F Barbero; Miguel Palma
Journal:  Sensors (Basel)       Date:  2020-05-31       Impact factor: 3.576

Review 5.  Current and future pharmacological therapies for managing cirrhosis and its complications.

Authors:  David Kockerling; Rooshi Nathwani; Roberta Forlano; Pinelopi Manousou; Benjamin H Mullish; Ameet Dhar
Journal:  World J Gastroenterol       Date:  2019-02-28       Impact factor: 5.742

Review 6.  cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease.

Authors:  Mohamed Elnagdy; Shirish Barve; Craig McClain; Leila Gobejishvili
Journal:  Biomolecules       Date:  2020-10-11

Review 7.  Prospects and Challenges for T Cell-Based Therapies of HCC.

Authors:  Norman Woller; Sophie Anna Engelskircher; Thomas Wirth; Heiner Wedemeyer
Journal:  Cells       Date:  2021-06-30       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.